<mets:mets OBJID="eprint_2534" LABEL="Eprints Item" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mets="http://www.loc.gov/METS/" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mets:metsHdr CREATEDATE="2026-07-04T20:14:14Z"><mets:agent ROLE="CUSTODIAN" TYPE="ORGANIZATION"><mets:name>Repositori BKPK</mets:name></mets:agent></mets:metsHdr><mets:dmdSec ID="DMD_eprint_2534_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:titleInfo><mods:title>TREATMENT OF SYMPTOMATIC VIVAX MALARIA IN BANGKA</mods:title></mods:titleInfo><mods:abstract>Background: Amodiaquine (AQ) showed very effective for treatment of symptomatic vivax malaria in Bangka. The combination of artesunate (ATS) and AQ was effective for treatment of uncomplicated falciparum malaria in Africa. This combination is a potential combination for both treatments of uncomplicated falciparum and vivax malaria in Indonesia. Combination of artemisinin (ART) and piperaquine (PPQ) is promising for future use because it is highly effective and safe, simple, and relatively cheap. We therefore canied out this trial to provide evidence whether the therapeutic efficacies of a :Hfay single daily dose regimen of combined ATS and AQ (ATS3+AQ3) were similar to a 2-day single daily dose regimen of ART and PPQ (ART2+PPQ2 )in both falciparum and vivax malaria.      Patients and methods: This trial was a prospective evaluation and a comparative study of the therapeutic efficacy of 3-day single daily dose regimen of combined ATS (4 mg/kg bw/dose) and AQ (25 mg base/kg bw in 3 days), and a 2-day single daily dose of ART (2.5 mglkg bw/dose) and     PPQ (15 mg/kg bw/dose) in uncomplicated falciparum and vivax malaria patients based on the new version of 2003 WHO protocol. The trial enrolled each arm 88 cases with a total of 176 uncomplicated falciparum malaria and 176 vivax malaria assuming proportion of treatment failures of both regimens were similar to 5% within confidence level of 95% and the precision of 5%. Patients were randomized, stratified by age (children and adults), and observed for 28 days. The primary endpoint was Adequate Clinical and Parasitological Response (ACPR) corrected by PCR. Analysis was by evaluability and intention to treat analysis.      Findings: The therapeutic efficacies of ATS3+AQ3 and ART2+PPQ2 were not different and effective for treatment of falciparum malaria and vivax malaria. Both regimens had high ACPR of &gt;90%, means of Fever Clearance Time and Parasite Clearance Time of &lt;1.5 days, hemoglobin recovery of &gt;95%, persistent gametocyte caniage in falciparum malaria patients over day 7, and common adverse reactions were nausea and vomiting to ATS3+AQ3 and ART2+PPQ2.      Interpretation: ATS3+AQ3 and ART2+PPQ2 were safe, tolerated, and efficacious for the treatment of falciparum malaria and vivax malaria. Primaquine should be given for radical cure as earlier as possible. Cost remains a problem for malaria control.</mods:abstract><mods:classification authority="lcc">WC 680-950 Tropical and Parasitic Diseases</mods:classification><mods:originInfo><mods:dateIssued encoding="iso8601">2005</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Pusat Penelitian dan Pengembangan Pemberantasan Penyakit</mods:publisher></mods:originInfo><mods:genre>Monograph</mods:genre></mets:xmlData></mets:mdWrap></mets:dmdSec><mets:amdSec ID="TMD_eprint_2534"><mets:rightsMD ID="rights_eprint_2534_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:useAndReproduction>
<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by its own author:</strong>
In self-archiving this collection of files and associated bibliographic
metadata, I grant Repositori BKPK the right to store
them and to make them permanently available publicly for free on-line.
I declare that this material is my own intellectual property and I
understand that Repositori BKPK does not assume any
responsibility if there is any breach of copyright in distributing these
files or metadata. (All authors are urged to prominently assert their
copyright on the title page of their work.)</p>

<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by someone other than its
author:</strong> I hereby declare that the collection of files and
associated bibliographic metadata that I am archiving at
Repositori BKPK is in the public domain. If this is
not the case, I accept full responsibility for any breach of copyright
that distributing these files or metadata may entail.</p>

<p xmlns="http://www.w3.org/1999/xhtml">Clicking on the <em>Deposit Item Now</em> button indicates your agreement to these
terms.</p>
    </mods:useAndReproduction></mets:xmlData></mets:mdWrap></mets:rightsMD></mets:amdSec><mets:fileSec></mets:fileSec><mets:structMap><mets:div DMDID="DMD_eprint_2534_mods" ADMID="TMD_eprint_2534"></mets:div></mets:structMap></mets:mets>